INNOVIVA, INC. Proceeds from Issuance of Subordinated Long-term Debt
INNOVIVA, INC. (INVA) reported Proceeds from Issuance of Subordinated Long-term Debt of $434.68 million for the 6-month period ending 2014-06-30, per its 10-Q filed 2014-08-07.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfSubordinatedLongTermDebt · last filed 2014-08-07
- INNOVIVA, INC. proceeds from issuance of subordinated long-term debt for the quarter ending 2014-06-30 was $434.68M.
- INNOVIVA, INC. proceeds from issuance of subordinated long-term debt for the quarter ending 2014-03-31 was $0.00, a 100.00% decline year-over-year.
- INNOVIVA, INC. proceeds from issuance of subordinated long-term debt for the quarter ending 2013-12-31 was $0.00.
- INNOVIVA, INC. proceeds from issuance of subordinated long-term debt for the quarter ending 2013-09-30 was -$1.00K.
- INNOVIVA, INC. proceeds from issuance of subordinated long-term debt for fiscal 2013 was $281.62M.
- INNOVIVA, INC. proceeds from issuance of subordinated long-term debt for fiscal 2012 was -$441.00K.
- INNOVIVA, INC. proceeds from issuance of subordinated long-term debt for fiscal 2011 was $0.00.
| Period end | Proceeds from Issuance of Subordinated Long-term Debt 3 month | Proceeds from Issuance of Subordinated Long-term Debt 6 month | Proceeds from Issuance of Subordinated Long-term Debt 9 month | Proceeds from Issuance of Subordinated Long-term Debt 12 month |
|---|---|---|---|---|
| 2014-06-30 | $434.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $434.68M 10-Q · filed 2014-08-07 | $434.68M derived: sum of 3 quarters · filed 2014-08-07 | $434.68M derived: sum of 4 quarters · filed 2014-08-07 |
| 2014-03-31 | $0.00 10-Q · filed 2014-05-07 | $0.00 derived: sum of 2 quarters · filed 2014-05-07 | -$1.00K derived: sum of 3 quarters · filed 2014-05-07 | -$51.00K derived: sum of 4 quarters · filed 2014-08-07 |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | -$1.00K derived: sum of 2 quarters · filed 2014-03-03 | -$51.00K derived: sum of 3 quarters · filed 2014-08-07 | $281.62M 10-K · filed 2014-03-03 |
| 2013-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-01 | -$51.00K derived: sum of 2 quarters · filed 2014-08-07 | $281.62M 10-Q · filed 2013-11-01 | |
| 2013-06-30 | -$50.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $281.62M 10-Q · filed 2014-08-07 | ||
| 2013-03-31 | $281.67M 10-Q · filed 2014-05-07 | |||
| 2012-12-31 | -$441.00K 10-K · filed 2014-03-03 | |||
| 2011-12-31 | $0.00 10-K · filed 2014-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |